- Home
- TIC vs SNDX Comparison
TIC vs SNDX Comparison
Compare TIC & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIC
- SNDX
- Stock Information
- Founded
- TIC 1991
- SNDX 2005
- Country
- TIC United States
- SNDX United States
- Employees
- TIC N/A
- SNDX N/A
- Industry
- TIC
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- TIC
- SNDX Health Care
- Exchange
- TIC Nasdaq
- SNDX Nasdaq
- Market Cap
- TIC 1.3B
- SNDX 1.1B
- IPO Year
- TIC N/A
- SNDX 2016
- Fundamental
- Price
- TIC $11.04
- SNDX $9.98
- Analyst Decision
- TIC Hold
- SNDX Strong Buy
- Analyst Count
- TIC 1
- SNDX 11
- Target Price
- TIC $11.50
- SNDX $34.00
- AVG Volume (30 Days)
- TIC 1.6M
- SNDX 1.8M
- Earning Date
- TIC 08-14-2025
- SNDX 08-04-2025
- Dividend Yield
- TIC N/A
- SNDX N/A
- EPS Growth
- TIC N/A
- SNDX N/A
- EPS
- TIC N/A
- SNDX N/A
- Revenue
- TIC $1,108,546,000.00
- SNDX $43,722,000.00
- Revenue This Year
- TIC $5.80
- SNDX $431.08
- Revenue Next Year
- TIC $5.77
- SNDX $105.38
- P/E Ratio
- TIC N/A
- SNDX N/A
- Revenue Growth
- TIC 9.12
- SNDX N/A
- 52 Week Low
- TIC $8.76
- SNDX $8.58
- 52 Week High
- TIC $14.28
- SNDX $22.98
- Technical
- Relative Strength Index (RSI)
- TIC N/A
- SNDX 52.38
- Support Level
- TIC N/A
- SNDX $9.42
- Resistance Level
- TIC N/A
- SNDX $10.75
- Average True Range (ATR)
- TIC 0.00
- SNDX 0.59
- MACD
- TIC 0.00
- SNDX 0.07
- Stochastic Oscillator
- TIC 0.00
- SNDX 55.23
About TIC Acuren Corporation Common Stock
Acuren Corp operates as a provider of critical asset integrity services. The company provides testing, inspection, engineering and lab testing services in different industrial markets such as chemical, pipeline, refinery, power generation, oilsands, automotive, aerospace, mining, manufacturing, renewable energy, and pulp and paper. The company's service line includes Nondestructive Testing (NDT) techniques such as radiography, ultrasonic testing, magnetic particle inspection, penetrant testing, etc., Rope Access Technician Solutions (RAT), and Engineering and Lab Testing. The company has two operating and reportable segments, which are the United States, generating maximum revenue, and Canada.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.